Search
Cerus Corp
CERSAdd to Watchlist
2.340USD
-0.170-6.77%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
468.74MMarket Cap
LossP/E TTM
More Details of Cerus Corp Company
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Cerus Corp Info
Ticker SymbolCERS
Company nameCerus Corp
IPO dateJan 31, 1997
CEOGreenman (William M)
Number of employees281
Security typeOrdinary Share
Fiscal year-endJan 31
Address1220 Concord Avenue
CityCONCORD
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94520
Phone19252886000
Websitehttps://www.cerus.com/
Ticker SymbolCERS
IPO dateJan 31, 1997
CEOGreenman (William M)
Company Executives of Cerus Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Kevin Dennis Green, CPA
Mr. Kevin Dennis Green, CPA
Chief Financial Officer, Vice President - Finance
Chief Financial Officer, Vice President - Finance
473.21K
+6.39%
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Independent Director
Independent Director
162.13K
-87.61%
Ms. Ann Lucena
Ms. Ann Lucena
Independent Director
Independent Director
112.28K
-62.14%
Dr. Hua Shan, M.D., Ph.D.
Dr. Hua Shan, M.D., Ph.D.
Independent Director
Independent Director
72.39K
-81.12%
Mr. William M. (Obi) Greenman
Mr. William M. (Obi) Greenman
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Ms. Chrystal N. Jensen, J.D.
Ms. Chrystal N. Jensen, J.D.
Chief Legal Office, General Counsel and Secretary
Chief Legal Office, General Counsel and Secretary
--
--
Dr. Frank R. Witney, Ph.D.
Dr. Frank R. Witney, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Richard J. Benjamin, Ph.D.
Dr. Richard J. Benjamin, Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vivek K. Jayaraman
Mr. Vivek K. Jayaraman
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Timothy L. (Tim) Moore
Mr. Timothy L. (Tim) Moore
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Kevin Dennis Green, CPA
Mr. Kevin Dennis Green, CPA
Chief Financial Officer, Vice President - Finance
Chief Financial Officer, Vice President - Finance
473.21K
+6.39%
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Independent Director
Independent Director
162.13K
-87.61%
Ms. Ann Lucena
Ms. Ann Lucena
Independent Director
Independent Director
112.28K
-62.14%
Dr. Hua Shan, M.D., Ph.D.
Dr. Hua Shan, M.D., Ph.D.
Independent Director
Independent Director
72.39K
-81.12%
Mr. William M. (Obi) Greenman
Mr. William M. (Obi) Greenman
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Ms. Chrystal N. Jensen, J.D.
Ms. Chrystal N. Jensen, J.D.
Chief Legal Office, General Counsel and Secretary
Chief Legal Office, General Counsel and Secretary
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Product
206.13M
88.17%
Government Contract
27.66M
11.83%
By RegionUSD
Name
Revenue
Proportion
United States
152.39M
65.18%
Other Countries
60.21M
25.75%
France
21.20M
9.07%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Product
206.13M
88.17%
Government Contract
27.66M
11.83%
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
9.56%
BlackRock Institutional Trust Company, N.A.
7.92%
Baker Bros. Advisors LP
5.00%
Soleus Capital Management, L.P.
4.91%
Vanguard Capital Management, LLC
4.06%
Other
68.55%
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
9.56%
BlackRock Institutional Trust Company, N.A.
7.92%
Baker Bros. Advisors LP
5.00%
Soleus Capital Management, L.P.
4.91%
Vanguard Capital Management, LLC
4.06%
Other
68.55%
Shareholder Types
Shareholders
Proportion
Investment Advisor
31.33%
Investment Advisor/Hedge Fund
20.52%
Hedge Fund
18.74%
Individual Investor
3.25%
Research Firm
2.19%
Family Office
1.22%
Pension Fund
0.64%
Bank and Trust
0.14%
Venture Capital
0.13%
Other
21.87%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
277
147.40M
73.57%
+4.48M
2025Q4
268
135.44M
74.92%
--
2025Q3
304
135.48M
76.42%
-3.67M
2025Q2
319
139.46M
80.29%
-3.80M
2025Q1
331
143.27M
81.50%
-8.15M
2024Q4
348
140.37M
85.99%
-4.57M
2024Q3
355
141.38M
83.08%
+1.94M
2024Q2
369
139.61M
83.57%
+2.55M
2024Q1
368
136.85M
84.80%
-16.89M
2023Q4
369
136.19M
88.68%
-5.81M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
ARK Investment Management LLC
18.20M
9.47%
-649.98K
-3.45%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
15.88M
8.26%
+294.39K
+1.89%
Dec 31, 2025
Baker Bros. Advisors LP
10.01M
5.21%
--
--
Dec 31, 2025
Soleus Capital Management, L.P.
9.83M
5.11%
+5.83M
+145.72%
Mar 23, 2026
Wasatch Global Investors Inc
5.46M
2.84%
-76.56K
-1.38%
Dec 31, 2025
BlackRock Financial Management, Inc.
4.90M
2.55%
+643.79K
+15.12%
Dec 31, 2025
Silvercrest Asset Management Group LLC
4.69M
2.44%
+562.14K
+13.63%
Dec 31, 2025
Amova Asset Management Co., Ltd.
4.71M
2.45%
-975.22K
-17.15%
Dec 31, 2025
Geode Capital Management, L.L.C.
4.49M
2.34%
-32.77K
-0.72%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ARK Genomic Revolution ETF
0.89%
Invesco NASDAQ Future Gen 200 ETF
0.6%
ARK Innovation ETF
0.18%
Fidelity Enhanced Small Cap ETF
0.06%
iShares Micro-Cap ETF
0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.05%
iShares US Small-Cap Equity Factor ETF
0.04%
iShares Russell 2000 Growth ETF
0.02%
Proshares Ultra Russell 2000
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
View more
ARK Genomic Revolution ETF
Proportion0.89%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.6%
ARK Innovation ETF
Proportion0.18%
Fidelity Enhanced Small Cap ETF
Proportion0.06%
iShares Micro-Cap ETF
Proportion0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.05%
iShares US Small-Cap Equity Factor ETF
Proportion0.04%
iShares Russell 2000 Growth ETF
Proportion0.02%
Proshares Ultra Russell 2000
Proportion0.01%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
